Serum fetuin-A is decreased in cirrhotic patients with Wilson's disease

PLoS One. 2023 Mar 7;18(3):e0282801. doi: 10.1371/journal.pone.0282801. eCollection 2023.

Abstract

Introduction: Wilson's disease may lead to cirrhosis, but timely medical treatment could slow down its progression. Clinical markers helping early diagnosis are essential. Decreased fetuin-A concentration has been reported in cirrhosis of different etiologies. The aim of this study was to investigate whether decreased serum fetuin-A concentration could identify patients with Wilson's disease who developed cirrhosis.

Materials and methods: In this cross-sectional study we determined the serum fetuin-A concentration of 50 patients with Wilson's disease. We analyzed the data of patients with liver involvement, comparing cirrhotic and non-cirrhotic patients.

Results: Among patients with liver involvement those with cirrhosis had significantly lower fetuin-A and albumin level, white blood cell and platelet count. Fetuin-A negatively correlated with disease duration, bilirubin level, positively with total protein and albumin concentration, but not with copper and ceruloplasmin concentrations or markers of systemic inflammation. In multivariate analysis with fetuin-A and the Nazer score or its parameters only fetuin-A was a significant determinant of having cirrhosis. In receiver operator curve analysis among patients with liver involvement the fetuin-A level of 523 μg/ml was associated with cirrhosis with 82% sensitivity and 87% specificity. The presence of the H1069Q mutation was not associated with alteration in fetuin-A concentration.

Conclusions: The serum concentration of fetuin-A is a sensitive marker of liver cirrhosis in Wilson's disease, independently of the H1069Q mutation, ceruloplasmin concentration or systemic inflammation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Albumins
  • Ceruloplasmin
  • Cross-Sectional Studies
  • Hepatolenticular Degeneration* / complications
  • Hepatolenticular Degeneration* / genetics
  • Humans
  • Inflammation
  • Liver Cirrhosis / complications
  • alpha-2-HS-Glycoprotein
  • alpha-Fetoproteins

Substances

  • alpha-2-HS-Glycoprotein
  • Ceruloplasmin
  • alpha-Fetoproteins
  • Albumins

Grants and funding

The procurement of some laboratory supplies was supported by the grant of the Hungarian Ministry of Health (ETT 278/2003). The authors received no financial support. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.